Why Cannabis and PTSD Require Careful Questions

PTSD can involve intrusive memories, avoidance of reminders, disturbed sleep, and feeling constantly on guard. Someone experiencing these symptoms may use cannabis hoping to relax, sleep, or manage pain. Understanding that motivation matters, even when the effectiveness of the coping strategy remains uncertain.

Three questions often become tangled together: whether cannabis provides immediate relief, whether it improves recovery over time, and whether cannabis use helps identify people experiencing distress. Each requires different evidence. Feeling calmer tonight does not establish that a treatment improves symptoms over several months.

MyCannabis’s overview of cannabis and PTSD treatment evidence explores why the product, symptom, and follow-up period matter. The new trauma study addresses a narrower question: how cannabis use and PTSD screening results appear together after intentional injury. It did not assign cannabis as a treatment.

How the Trauma Recovery Study Worked

Researchers at an urban academic Level 1 trauma center analyzed 69 adults injured through gunshots, stabbings, or blunt assault. All screened negative for PTSD at baseline and had the information required for follow-up analysis. Participants completed assessments at either six or twelve months after injury.

The team used the Primary Care PTSD Screen for DSM-5, a five-question screening tool. A score of three or more counted as positive. Screening identifies people who may need further evaluation; it does not establish a clinical diagnosis.

Participants also reported cannabis use and completed a questionnaire covering health domains such as pain, anxiety, depression, sleep, and physical function. For the main analysis, researchers grouped cannabis use at least once or twice weekly together. Occasional use and never using cannabis formed the comparison category.

That definition is essential. The findings compare regular use with occasional or no use, rather than comparing everyone who ever consumed cannabis with people who never did.

What the Cannabis and PTSD Findings Showed

At follow-up, 31 participants screened positive for PTSD and 38 screened negative. Regular cannabis use was reported by 42% of the positive-screen group, compared with 13% of the negative-screen group. Baseline cannabis use also differed: 29% versus 3%, respectively.

After adjustment for demographic and injury characteristics, follow-up cannabis use was associated with 7.1 times greater odds of a positive PTSD screen. That figure describes an association in this sample. It does not mean cannabis caused a sevenfold increase in someone’s probability of developing PTSD.

Participants screening positive for PTSD also reported poorer outcomes across the health domains measured. However, comparisons based specifically on follow-up cannabis use found a statistically significant difference only in sleep disturbance. These are different comparisons, and combining them would incorrectly suggest that cannabis users had worse results across every domain.

The Most Useful Finding May Be a Screening Blind Spot

One detail in the paper deserves particular attention: researchers introduced a cannabis-specific question after anecdotal indications that some participants using marijuana were not reporting it under a general question about drug use.

This suggests a possible mismatch between clinical language and how patients understand their behavior. Someone may regard cannabis as a sleep aid, a legal consumer product, or a familiar coping tool. A broad question about drugs may fail to capture that use, even without deliberate concealment.

The practical implication is straightforward. Asking specifically about cannabis could produce a more complete picture than relying on a broad substance-use category. The study does not establish how much this change improves detection, but it identifies a plausible gap worth testing.

A more informative conversation could explore:

• How often cannabis is used and what the person hopes it helps.
• Whether use changed after injury or alongside changing symptoms.
• How sleep, daily activities, and emotional wellbeing have changed.

The researchers also emphasize explaining how responses will be recorded and used. Clear communication could help make disclosure feel relevant to care, rather than an invitation to judgment.

Why Association Cannot Explain the Direction

Several explanations could produce the observed pattern. Distress might encourage more frequent cannabis use. Cannabis could affect symptoms for some people. Pain, continuing threats, limited support, or other circumstances could influence both. More than one pathway may operate within the same person.

Think of a photograph showing someone holding an umbrella on a wet street. The image connects umbrellas with rain, but it cannot reveal when the umbrella opened. Likewise, measurements at baseline and one later visit cannot reconstruct the sequence between changing cannabis use and emerging symptoms.

The uncertainty is substantial. The adjusted estimate’s 95% confidence interval ranged from 1.7 to 29.5, reflecting limited precision. The study involved one center and only 69 participants, and its cannabis measure did not distinguish THC strength, CBD content, dose, or route of consumption.

The uploaded manuscript is also an accepted journal pre-proof. Its abstract and methods describe the regression outcome inconsistently, although Table 2 and the main results identify a positive PTSD screen as the outcome. The defensible conclusion remains an association requiring further investigation.

Relief, Sleep, and Recovery Need Separate Measures

Sleep illustrates why recovery needs several measures. A person may value feeling relaxed at bedtime while still experiencing disrupted nights or daytime fatigue. Those experiences deserve attention individually, rather than being compressed into a single question about whether cannabis helps.

Recent MyCannabis coverage of the gap between reported sleep benefits and clinical evidence examines this distinction. In the trauma study, regular cannabis users more often reported substantial sleep disturbance, but the researchers could not establish whether sleep problems preceded cannabis use.

For future studies, asking why someone consumes cannabis may be as useful as asking how often. Use motivated by nightmares, persistent pain, or recreation could represent different circumstances, even at the same weekly frequency.

Better Cannabis Conversations Can Support Better Care

These findings support a broader view of recovery, with cannabis discussions connected to psychological assessment and follow-up. They do not establish cannabis as a PTSD treatment. The VA National Center for PTSD’s clinical overview explains that current VA/DoD guidance recommends against cannabis for treating PTSD and supports addressing co-occurring conditions together. Cannabis use should not automatically exclude someone from trauma-focused care.

There is also room for more precise research. Canada’s August 2026 announcement of a national cannabis and brain health research consortium reflects continuing investment in understanding benefits and harms across different populations.

The next useful experiment would test whether cannabis-specific questions, repeated symptom assessments, and reliable referrals improve recognition and recovery compared with usual screening. That would move beyond observing an association toward measuring whether a change in care actually helps.

References:

¹ Kern, J. A., Wilson, C., Joshi, S. A., Ghio, M., O’Neill, K., Reese, J., Babb, R., Emili, P., Williams, A., Seamon, M., & Kaufman, E. J. (2026). The blunt truth: The role of marijuana in PTSD after intentional traumatic injury. Injury. Advance online publication. https://doi.org/10.1016/j.injury.2026.113789